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Abstract: Recent advances in molecular
biology enable researchers to understand the
basis of breast cancer much better and show
that hereditery breast cancer may result from
mutations on several specific gene loci
including BRCA1, BRCA2, p53, ATM and
PTEN. These genes are tumor supressor
genes and although their functions are
different, they are all involved in the
maintenance of genomic stability after DNA
damage. Mutations that impair the function of
these genes may adversely affect the manner
in which DNA damage is processed. It is likely
that the risk of breast cancer development is
increased through this mechanism. Moreover,
there are several predispositions, such as the
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Introduction
Literature about breast cancer dates back to the
second half of the 19th century. Due to the lack of
genetic knowledge, studies until the 20th century were
on the epidemiological level. Until 1990, there was no
progress in the characterization of breast cancer genes. In
the early 1990’s, some investigators showed certain
mutations of the p53 gene involved in the development of
breast cancer. Afterwards, BRCA1 and BRCA2 genes
were discovered to play a role in breast cancer (1). Since
then, other genes and chromosomal abnormalities have
been found to participate in the carcinogenesis of breast
tissues. Thus, information regarding the formation of
breast cancer at the genetic level has been obtained.
In breast tissue, the hormone-sensitive cells in the
terminal duct-lobular unit contain the stem cells that
generate the lactating lobules. These cells are responsive
to estrogen and progesterone, which provide signals for
growth during the menstrual cycle and elicit proliferation
during pregnancy. Should the individual carry a germline
or somatic mutation in tumor supressor genes, the stem
cells in the terminal ductal-lobular unit are predisposed to
malignancy, but these cells are quiescent in prepubertal

androgen receptor gene (AR) and the HNPCC,
that may also be involved, but further studies
are required in order to understand the extent
of their involvement in breast cancer. In this
paper, we supply data on the general function
of the tumor supressor genes indicated above.
We also review probable mutations of these
genes and their relevance to breast cancer
development. Furthermore, we discuss
estrogen genes and estrogen receptor genes
that may be involved in breast cancer
development, as indicated in the recent
studies.
Key Words: BRCA1, BRCA2, p53, ATM,
PTEN and Estrogen

life, and no tumor can form. When these cells are
subjected to hormone stimulation during puberty, their
DNA is replicated to permit cell proliferation. However, if
there is a genetic defect in p53 or in the other genes, the
control and regulation of replication cannot be carried out
in a proper manner. Therefore, cells start proliferating in
an uncontrolled way, thus causing instability and
activation of proto-oncogenes. Some oncogenes also
initiate gene amplifications (erbB2, c-myc, int-2), leading
to tumorogenesis (2). Although the activation of
oncogenes has clear relevance in selected breast cancer
cases, a more common finding in breast cancer cells is a
mutation in one or more tumor suppressor genes. As a
class, these genes function to maintain genomic integrity
and help prevent the propagation of damaged DNA.
Aberration in many tumor suppressor genes directly
affects cellular susceptibility to DNA damage and cellular
capacity DNA damage repair. Others recognize damaged
DNA and promote cell cycle arrest, allowing for repair of
damage before DNA synthesis and mitosis commence.
Finally, tumor suppressor gene products may also inhibit
propagation of damaged DNA by inducing apoptotic
cellular death (3).
1
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Although it has been demonstrated that mutations of
p53, BRCA1 and BRCA2 can lead to increased breast
cancer risk, the percentage of these mutations is
comparatively low in breast cancer cases (only 6% to 8%
of the total United States breast cancer population) (4,
5). In addition, these genes are not found in all cases of
familial breast cancer. Therefore, further studies should
be carried out to isolate germline genetic etiologies. In
this respect, studies are being conducted to discover new
genes related to breast cancer, and in particular it has
been indicated that the involvement of estrogen in
breast cancer may be much deeper than was originally
thought.
BRCA1 and BRCA2
The identification of the BRCA1 and BRCA2 genes will
have vast significance in furthering our understanding of
breast pathogenesis. These two genes are tumor
supressor genes shown to be involved not only in breast
cancer but also in ovarian and prostate cancers (Table).
BRCA1 and BRCA2 are responsible for 80-90% of all
familial breast cancer (6). The BRCA1 gene, mapped to
chromosome 17q21, is a large one (Fig. 1). It spans 100
kb of genomic DNA and encodes a protein of 1863 amino

Table.

acids. This gene, transcribed in several tissues, was found
to be most abundantly expressed in the thymus, testis,
breast and ovary (Table). It is known that the gene does
not have homology with other genes except for the zinc
finger domain at the N-terminus and a heptad repeat
element in the middle of the protein, which might
enhance dimerization. BRCA1 product is involved in DNA
repair, transcriptional transactivation, apoptosis and cell
cycle control (1,7-9). How does BRCA1 perform these
functions? Experiments conducted so far indicate that
wild type BRCA1 protein binds to a number of cellular
proteins, including DNA repair protein Rad 51, tumor
supressor p53, RNA polymerase II holoenzyme, RNA
helicase A, CtBP-interacting protein, c-myc, BRCA1associated RING domain protein (BARD1), BRCA2
protein, etc. These proteins probably mediate functions
of BRCA1. Therefore, mutations in BRCA1 may affect the
composition of these complexes and disregulation of their
functions may eventually result in the devolopment of
malignancy (Fig. 2) (10).
It was also found that BRCA1 has two variants,
BRCA1a and BRCA1b, which are phosphoproteins
containing phosphotyrosine (11). These proteins are

Summary of genes involved in breast cancer.

Cloned gene

Chromosome
location

Proposed function of gene product

Primary tumor

Associated cancers
or traits

Syndrome

BRCA1

17q21

Interacts with Rad 51 protein;
Repair of double-strand breaks; involved
also in transcriptional transactivation
apoptosis and cell cycle control.

Breast cancer

Ovarian cancer

Familial
breast cancer

BRCA2

13q12

Interacts with Rad 51 protein; repair of
double-strand breaks; Also has a role in
transcriptional regulation.

Breast cancer

Male breast cancer,
cancer, pancreatic,
?others (for example,
ovarian)

Familial
breast cancer 2

p53

17p13.1

Transcription factor; response to DNA
damage and stress; apoptosis

Sarcomas,
breast cancer

Brain tumors,
leukemia

Li-Fraumeni
Syndrome

ATM

11q22

DNA repair, induction of p53,
phosphorilation of c-Abl and BRCA1

Lymphoma

Cerebellar ataxia,
immunodeficiency,
breast cancer in
heterozygotes

Ataxia
telengiectasia

PTEN

10q23

Control PIP3 pathway in cell growth,
keep cell population in check.

Glioma

Menengiomas, prostate
cancer, breast cancer

Cowden’s
disease
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DNA
Ionizing Radiation

Fig. 1.

Ideogram of human chromosomes
10, 11,13 and 17 showing the
position of PTEN, ATM, BRCA2,
BRCA1 and p53 respectively.

Fig. 2.

A schematic diagram of possible
pathways by which BRCA genes
affect DNA damage repair.

DNA Damage
Transcriptioncoupled
repair
BRCA1

ATM

BRCA1
Rad51

BRCA2

Rad51

P53

BRCA2

C-Abl

Homologous recombination
Repair

Repaired DNA

associated with E2F, cyclins and cyclin dependent kinases.
These findings suggest that BRCA1 could be an important
negative regulator of cell cycle that functions through
interaction with E2F transcriptional factors and
phosphorylation by cyclins/cdk complexes, with zinc ring
finger functioning as a major protein-protein interaction

domain. But these interactions are observed in vitro. If
they are also observed in vivo, then it may be that the lack
or impaired binding of the disrupted BRCA1 proteins to
E2F and cyclins/CDKs in patients with mutations in the
zinc finger domain could deprive the cell of an important
mechanism for braking cell proliferation, leading to the
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development of breast and ovarian cancers. BRCA1a and
BRCA1b also interact with p53 in vitro and in vivo. These
results demonstrate the presence of a second p53
interaction domain in BRCA1 proteins and suggest that
BRCA1a and BRCA1b proteins, like BRCA1, function as
p53 co-activators (12).
A great variety of germline mutations are thought to
result in the synthesis of a truncated BRCA1 protein.
Although most mutations have been identified in only one
or two families, a limited number of them have been seen
recurrently (13). The nature of mutations are displayed
and it was shown that these mutations form allelic
variants of BRCA1 (Fig 3). Of these, the most common is
the variant BRCA1, 2-BP DEL, 185AG, which includes a
deletion of the normal sequence TTA GAG of codons 2223 in exon 3. These mutations alter the reading frame of
the mRNA and cause a premature termination at position
39 (14). Of particular interest, frameshift mutations at
codon 185 of BRCA1 have been identified in more than
20 Jewish families with familial breast or ovarian cancer.
A recent population survey of Ashkenazi Jews, chosen
without regard to family history of cancer, has
demonstrated that about 1% carry the 185delAG
mutation (15). Thus, as suggested by Collins, familial
breast and ovarian cancer attributable to the 185delAG
mutation is potentially the most common serious singlegene disorder yet identified in any population group (16).

Fig. 3.

4

Based on epidemiologic studies, the life-long risks of
breast cancer and ovarian cancer in individuals carrying a
mutant BRCA1 allele have been estimated at 85% and
50% respectively (13). BRCA1 mutations have been
observed in roughly 10% to 15% of women who had
developed breast cancer before the age of 35. In Jewish
women who developed breast cancer before the age of
40, BRCA1 mutations were seen in over 20% (17).
Based on the fact that the LOH of the BRCA1 locus
was seen in 50% of unselected breast tumors and in 60%
to 65% of unselected ovarian tumors (18), the BRCA1
protein was hypothesized to play an important role in the
development of sporadic breast and ovarian cancers.
Surprisingly, very few tumors have been found to harbor
detectable somatic point mutations in BRCA1 (18).
Hence, these findings have raised questions regarding the
role of the BRCA1 gene in sporadic breast and ovarian
cancers. However, two recent reports have suggested a
role for the BRCA1 gene in sporadic tumors. Somatic
BRCA1 mutations have been identified in at least a few
sporadic ovarian carcinomas (19). Moreover, a recent
study has hinted that the function of the BRCA1 protein
may indeed be altered in the majority of breast and
ovarian cancers. Specifically, it was found that the BRCA1
protein normally localized in the cytoplasm in the majority
of breast and ovarian carcinoma cell lines and primary
tumors evaluated (20). These findings suggest that

Germline mutations reported in the BRCA1 gene predominantly from families with high incidence of breast and/or ovarian cancer. The
numbers correspond to BRCA1 exons; there is no exon 4. The nature of the mutations and whether they have been seen in more than one
apparently unrelated individial (i.e., recurrent) are indicated. (From Collins, 1996, with permission).
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BRCA1 abnormalities, the nature of most of which is as
yet unknown, may play an important role in many
sporadic as well as familial breast and ovarian cancers.
On the other hand, functions of BRCA1 have been
observed in various human epithelial cancer cell types and
mouse fibroblast and do not explain the association of
BRCA1 mutations with specific tumor types, such as
breast cancer. Estrogen stimulation of the mammary
epithelia is thought to be a major factor in promoting the
development of breast cancer, probably through the
expansion of previously initiated mammary epithelial cell
clones (21). Thus, S. Fun and his colleagues hypothesized
that the BRCA1 protein might function, in part, to
regulate the cellular response to estrogen. To assess the
effect of BRCA1 on estrogen response, they measured
the ability of the BRCA1 gene to modulate the
transcriptional activity of ER-α in transient transfection
assays. They found that the wild-type BRCA1 gene
(wtBRCA1) inhibits ER-α signaling in breast cancer cell
line T47D, in two other human breast cancer cell lines
(MCF7 and MDA-MB-231), and in two human prostate
cancer cell lines (LNCaP and TsuPr-1) . However, three
human cervical cancer cell lines showed relatively weak
inhibition of ER-α signaling by BRCA1. But these
observations are hypothetical and to establish the validity
of these hypotheses, it is necessary to confirm the ability
of BRCA1 to regulate the ER-α response in in vivo models
(22).
While germline mutations in the BRCA1 gene account
for upwards of half of the families in which many
members are affected by breast cancer, other cases of
familial breast cancer susceptibility have been attributed
to mutations of another highly penetrant autosomal
dominant susceptibility gene termed BRCA2. The BRCA2
gene was mapped to chromosome 13q12-13 in 1994
and was recently characterized. BRCA2 is larger than
BRCA1, with a coding sequence of 10 254 base pairs
encoding 3418 amino acids and 26 coding exons (23-26).
The BRCA2 protein, like BRCA1, plays a role in
transcriptional regulation and DNA repair (Fig. 2). It has
been shown that BRCA2 has transcriptional activation
potential conferred by its amino terminal third exon.
Published results (1998) present evidence that BRCA2
has intrinsic HAT activity, which maps to the aminoterminal region of BRCA2. In this study it is also
demonstrated that BRCA2 proteins acetylate primarily
H3 and H4 of the free histones. These observations

suggest that the HAT activity of BRCA2 may play an
important role in the regulation of transcription and
tumor supressor function (27). But, in another study by
Fuks and his co-workers, no evidence was found in
support of an intrinsic HAT activity in the BRCA2 amino
terminus. They also show that BRCA2 interacts with a
transcriptional co-activator protein, P/CAF, which
possesses histone acetyltransferase activity. The
interaction with P/CAF is demonstrated in vitro as well as
in vivo and is shown to be mediated by residues 290-453
of BRCA2. Thus, the Fuks team suggests that one
mechanism by which BRCA2 regulates transcription may
be through the recruitment of the histone modifying
activity of the P/CAF (28).
BRCA2 undergoes differential splicing, giving rise to a
novel variant protein, BRCA2a, lacking putative
transcriptional activation domain. Both BRCA2 and
BRCA2a are expressed at high levels in the thymus and
testis but at moderate levels in the mammary gland and
prostate, suggesting that BRCA2 and BRCA2a play a role
in the development and differentiation of these tissues
(29).
Mutations in BRCA1 and BRCA2 appear to confer
essentially similar risks of female breast cancer. The risk
of ovarian cancer is lower in those with BRCA2
mutations, though the risk of male breast cancer in those
with a BRCA2 mutation is substantially higher. The risk
of other cancers, including laryngeal and prostate, may
also be elevated in carriers of BRCA2 (24). Loss of
heterozygosity involving the BRCA2 locus at 13q12 (Fig.
1), but not the RB1 locus at 13q14, has been observed in
sporadic breast, pancreatic, head and neck, and other
cancers, suggesting that there is a somatically mutated
tumor suppressor gene in the vicinity of BRCA2. BRCA2
is a strong candidate for this gene. Finally, the predicted
sequence of the BRCA2 protein has shed little light on its
function, though preliminary studies have shown that it
bears a very weak similarity to the BRCA1 protein over a
restricted region of sequence (24). The significance of
this finding is unclear.
P53
p53 mutations are very prevalent in a wide spectrum
of human cancers (Table ). Indeed, p53 is believed to be
one of the most commonly mutated genes in human
cancer (30). The p53 gene is located on chromosome
17p13.1 (Fig. 1), contains 393 codons and codes for a
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nuclear protein of 53 000 D (53 kD). A region with
transcription activating (ACT) properties is located at the
N-terminal end of its gene product. The HSP domain
(coded for codons 13-29) of mutant p53 can bind to
heat-shock proteins. A serine residue at position 315 can
become phosphorylated by the product of the CDC2 gene,
a gene in cell-cycle regulation. The p53 protein is a
transcription factor and plays an important role in
regulating growth in damaged cells as well (31).
As indicated above, mutations in the p53 gene are the
most frequent genetic changes in cells in different
malignant tumors of man. Mutations in the p53 gene
frequently occur (in 12-13% of all tumors) in codons
175, 248 and 273 (32). Detailed characterization of the
mutations present in p53 has revealed that the pattern of
DNA base substitutions is distinctly different in different
types of cancers.
In primary breast cancers, mutations of the p53
tumor suppressor gene are common and lead to loss of
growth-suppressive properties and poor outcome (33).
Approximately 20% to 40% of human breast cancers
have mutations in the p53 gene (34). Individuals with a
p53 germline mutation (Li-Fraumeni syndrome) have
very high risks of breast cancer and other malignancies
(35). Cancer risks in individuals with a germline p53
mutation are estimated to be 50% by the age of 30 and
90% by the age of 70 (36). In a study of 231 patients
with germline p53 mutations, breast cancer was the most
common malignancy (37). Smith and his colleagues have
indicated that inheritance of germline mutant alleles of
BRCA1 and BRCA2 confers a markedly increased risk of
breast cancer. In their previously published study, it was
reported that p53 mutations have a higher incidence in
these tumors. They have characterized these new p53
mutants. The rarity of these mutants in human cancer
and their multiple occurrence in BRCA-associated breast
tumors suggest that these novel p53 mutants are selected
during malignant progression in the unique genetic
background of BRCA1 and BRCA2 associated tumors
(38). Breast cancers occurring in BRCA1 mutation
carriers had significantly higher levels of p53 expression,
including the preinvasive (carcinoma in situ) stage of
disease, compared with cancers occurring in BRCA2
mutation carriers or women with no detectable germline
mutation (39). Direct p53 mutation analyses revealed
mutations in 18% of all of the early-onset breast cancers
within the study and included rare insertion and deletion
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mutations in cancers from BRCA1 mutation carriers.
Likewise, several studies indicate that the short arm of
chromosome 17 is one of the most frequently altered
regions in sporadic breast carcinomas (45-60%) (40). In
this regard, the study by Liscia’s team is further evidence
of the presence, within the region, of at least a second
tumor suppressor gene distal to p53, which might be
targeted by deletions.
On the other hand, it was demonstrated that 17βestradiol (E2) induces p53 protein expression in breast
cancer cells. Direct effects of E2 on the expression of the
p53 gene are not known but it is clear that the steroid is
a potent regulator of c-Myc transcription. In a study
published by Hard’s team, the ability of E2 and
antiestrogens has been examined to regulate the P1
promoter of the p53 gene which contains a c-Myc
responsive element. In the end, they demonstrate both
ER-mediated and ER-independent regulation of c-Myc
and P1 promoter of the p53 gene, and show differential
effects of the two classes of antiestrogens in their ability
to induce the P1 promoter of the p53 gene in breast
cancer (41).
Recently, two p53-related genes, p63 and p73, were
discovered. As it might be predicted, both genes encode
proteins with transactivation, DNA binding and
tetramerization domains, and they share considerable
homology with p53 (42). Ectopic p73 expression can
activate a broad subset of p53 responsive genes, induce
apoptosis, and act as a growth suppressor. Many of p53’s
targets can be transactivated by some isoforms of p63
and p73. Some forms also induce cell-cycle arrest and
apoptosis. This shows that some p53 independent cellular
responses are given by these p53 relatives (42). It was
also found that p73 is a target of the non-receptor
tyrosine kinase c-Abl in response to DNA damage (Fig. 4)
(43-45). Zaika and his colleagues analyzed 77 invasive
breast cancers and 7 breast cancer cell lines for p73
mRNA expression levels, allelic origin, intragenic
mutations, and COOH-terminal splice variants. They
found that p73 is overexpressed in breast cancer, and
also found six different COOH-terminal splice variants.
They confirm the previously described variants gamma
and delta in breast tissue and describe two novel
isoforms, p73 epsilon and phi, thereby further enlarging
the combinative possibilities. In conclusion, their in vivo
data show that p73 does not play a role as a classic
Knudson-type tumor suppressor in breast cancer (46).
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In the other study, related p73 has been elucidated
the functional significance of the gene in the oncogenesis
of breast cancer. But observations regarding this study
suggest that allelic loss, expression levels and mutations
of the p73 gene may not contribute to the oncogenesis of
primary breast cancers (33).
ATM
In recent studies, it has been shown that the gene for
ataxia telangiectasia (AT), called ATM, may play a role in
the development of breast cancer (Table). The ATM gene
has been recently cloned and characterized. This gene was
identified by positional cloning on chromosome 11q2223 (Fig. 1) (48). The gene codes for a large RNA
transcript of 13,000 bp, of which a 3 500 amino acid
protein is translated. ATM itself covers 150 kb, spreading
over 64 exons (44). In another study, it was shown that
the ATM gene product, a component of the DNA-damage
checkpoint interacts with and phophorylates c-Abl (Fig. 4)
(49-51). The ATM protein is a widely expressed member
of the family of protein kinases with similarities to
phosphotidylinositol 3-kinases (42). The amino acid
sequence has revealed the existence at the
carboxyterminal end of the protein, of a domain
presenting homology to PI-3 kinase. This characteristic
has allowed the description of a new family of nuclear
proteins, in yeast, drosophila and humans, functionally
involved in DNA damage signaling (48). It is interesting to
note that a vast majority of mutations described in AT
patients lead to the truncation of the protein and
consequently to the elimination of the PI-3K domain.

Thus, loss of ATM function in human and mouse cells
causes defects in DNA repair and cell-cycle checkpoint
control and this leads to susceptibility to cancer (42).
Furthermore, after ionizing radiation, c-Abl also interacts
with DNA-PK and DNA-end binding protein ku (52). DNAPK can induce c-Abl activity and also appears to be an
upstream mediator of p53 activity (53). This regulatory
interaction of ATM, c-Abl, DNA-PK and p53 appears to be
one critical link of DNA damage repair and cell cycle
regulation. There is strong evidence that a key
downstream target of ATM is p53, which is
phosphorylated and stabilized by ATM in response to DNA
damage (54-56).
Patients who are homozygous for ataxia telangiectasia
(AT) have an exceptionally high incidence of cancer. An
important question linked to AT mutation concerns the
cancer risk associated with heterozygous mutations. It is
well established that AT patients, homozygous for the
mutation, present a 100-200 fold increased risk of
cancer. Epidemiological studies have described a 3-5 fold
increase risk of cancer (particularly breast cancer in
women) associated with the heterozygous mutation.
Knowing that the incidence of the heterozygotes can be
estimated to range from 0.5 to 1% in the general
population, this question is of great importance in terms
of public health (48).
AT heterozygotes (estimated to be in 1% of the
population) do not show any of the major symptoms of
the disease, though there is good evidence that they have
an underlying cellular radiosensitivity, but to a lesser
7
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extent than observed in AT homozygotes (57). These
observations, together with earlier epidemiological
studies, reveal an increased incidence of mortality from
cancer among blood relations of patients with ataxia
telangiectasia, with the greatest relative risk for breast
cancer in female relatives of patients (58).
An association between the incidence of breast cancer
and AT heterozygosity was also revealed in two separate
but smaller studies (59-60). Based on an independent
assessment of all these data, the relative risk of breast
cancer in AT heterozygotes was estimated to be 3.9, with
AT carriers representing 3.8% of all cases (61).
With knowledge of the sequence of the ATM gene,
FitzGerald and his co-workers detected heterozygous
mutations in 2/202 healthy women (1%) with no
personal history of cancer (62). The frequency of 1% is
consistent with that predicted from epidemiological
studies (58). When patients with early onset breast
cancer (<40 years) were screened, 2/410 (0.5%) showed
mutations in the ATM gene. FitzGerald and his coworkers therefore concluded that "heterozygous ATM
mutations do not confer genetic predisposition to early
onset breast cancer." On the other hand, a recent study
by Athma and his colleagues using molecular genotyping
suggested that AT heterozygotes are predisposed to
breast cancer (63). Among 33 women with breast cancer,
25 were AT heterozygotes, compared with an expected
15. For patients with earlier onset disease (<60 years)
the odds ratio was 2.9 (21 cases) and for older patients
it was 6.4 (12 cases). Based on these relative risks, the
authors calculated that 6.6% of all cases of breast cancer
in America occur in AT heterozygotes.
Clearly, these two studies appear to be in conflict. In
an analysis of these data, Bishop and Hoppe pointed out
that precise estimates were difficult since the study of
FitzGerald and his co-workers relied on a small number
of mutations while that of Athma and his colleagues
analyzed only a small number of breast cancers (64).
Larger scale studies are required with emphasis on age of
onset of breast cancer to address conclusively the
potential association between mutations in ATM and risk
of developing breast cancer. In a workshop held last
November in Clermont-Ferrand, results were presented
from studies in several countries, but the connection
between AT heterozygosity and breast cancer remains
unresolved.
8

For AT carriers, the picture that emerges is that while
epidemiological studies point to a threefold to fourfold
increased risk for breast cancer, there remains
uncertainty as to whether this is supported by mutation
analysis of the ATM gene. Screening of increased
numbers of patients with breast cancer is required to
support a small moderate increased relative risk for AT
heterozygotes. It seems unlikely that the intermediate
cellular radiosensitivity in AT carriers increases the risk of
breast cancer during mammographic screening, at least
when this procedure is restricted to women over the age
of 40 (65). However, Appleby and his colleagues suggest
that screening for ATM mutations in cancer patients may
not be of value in predicting adverse reactions in the AT
heterozygotes (66).
In a study by Clarke and his co-workers, it was shown
that normally ATM is not upregulated after DNA damage,
but in the proliferative myoepithelium of sclerosing
adenosis, ATM expression increases significantly. The
authors also indicated that there are factors other than
ATM mutations that can dramatically influence ATM
expression in the breast and that these factors should be
considered for their possible implications in
carcinogenesis (67).
In addition, Laake and his colleagues found three
distinct regions at 11q23.1 that may be involved in breast
development; one between the markers D11S1294 and
D11S1818, a second at APOC-3, and a third that is
possibly the ATM gene itself (68). Waha and his coworkers found that concentrations of the ATM
transcripts in breast carcinomas were low, in benign
lesions levels were intermediate and in normal breast
tissue specimens levels were highest (69). Moreover, in
the particular note of Rio and his colleagues, it was
indicated that LOH of ATM was correlated with higher
grade and a lower age of diagnosis in ductal breast
carcinoma (70).
PTEN
Recently, two research teams separately homed in on
a tumor suppressor gene, the loss or inactivation of which
may be important for the progression of many cancers
such as brain, breast and prostate (Table). This gene was
called PTEN by the Parsons group (71) and MMCA by
Steck and his colleagues and joins some 16 other known
tumor suppressors (72). This gene has been mapped on
human chromosome 10q23 (Fig. 1). PTEN is a
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phosphatase but, unlike other phosphatases, its target is
apparently not a protein. Instead, it is a fatty molecule, or
lipid, that is tucked into the cell membrane. The target
lipid is phosphatidylinositol-3,4,5-triphosphate (PIP3)
and is a key component of one the cells major growth
control pathways, acting both to stimulate cell growth
and to block apoptosis, a form of cell suicide that can
keep damaged cells from proliferating. By stripping away
one of PIP3’s three phosphates, it appears, PTEN reins in
the growth pathways and allows cell suicide to proceed,
keeping cell population in check.
Conversely, loss of PTEN during tumorigenesis
presumably keeps the PIP3 pathway inappropriately
activated, allowing the mutated cells to grow unchecked
when they should die (73).
In preliminary screens, mutations of PTEN were
detected in 31% (13/42) of glioblastoma cell lines and
xenografts, 100% (4/4) of prostate cell lines, 6% (4/65)
of breast cancer cell lines and xenografts, and 17%
(3/18) of primary glioblastoma (71).
Tonks and his colleagues have reported that the
normal gene inhibits the growth of the cells. However,
the gene with the mutation has lost its ability to prevent
the cells from proliferating. Tonks’s team suggests that
mutant PTEN lacks lipid phosphatase activity, but that its
protein phosphatase activity remains intact (74). Webster
Cavenee and Frank Furnari have also looked at a handful
of PTEN mutants, and, in a test tube assay, have found
that every mutation that renders the protein useless as a
tumor supressor, eliminates its lipid phosphatase activity
(75).
Although Wigler and the Parsons team detected PTEN
in breast cancer, new studies in this area seemed to be
controversial. Feilotter and his team analyzed the
chromosomal region of the 10q23 and the PTEN gene in
human sporadic breast cancer. They used a combination
of denaturating gradient gel electrophoresis and SSCP
analysis to investigate the presence of PTEN mutations in
tumor with LOH in this region. They did not detect
mutations of PTEN in any of these tumors. Their data
show that in sporadic breast carcinoma, loss of
heterozygosity of the PTEN locus is frequent, but
mutation of PTEN is not. They suggested that these
results are consistent with loss of another unidentified
tumor suppressor in this region in sporadic breast
carcinoma (76).

Another team characterized a breast cancer cell line
derived from a germline BRCA1 mutations carrier and
found that this cell line carried an acquired homozygous
deletion of the PTEN gene (77).
Bose and his colleagues analyzed in situ invasive
carcinomas to determine the status of chromosome
10q23 in primary breast carcinomas. They used
microsatellite markers spanning the 10q23 region to
analyze allelic loss. No LOH was seen in pure intraductal
carcinomas (0/20 cases). On the other hand, LOH was
observed in 40% (17/42) of invasive carcinomas
(P=0.0005). Interestingly, in situ lesions found in
invasive tumors displayed LOH. Allelic loss was also
significantly associated with loss of the estrogen receptor
(P=0.011). Thus, loss of the 10q23 is strongly associated
with tumor progression (78).
In contrast, other results suggest that mutation of the
PTEN /MMCA does not play a major role in breast cancer
(79, 80) and that germline mutations in PTEN are an
uncommon case of genetic predisposition to breast cancer
within the general population.
Role of Estrogen in Breast Cancer
It has been known for some time that there is a link
between estrogen and cancer. Both epidemiological and
cell biology studies have indicated that it contributes to
the development of the top five cancers of women_those
of the breast, uterus and ovaries_which together account
for an estimated 240,000 new cancer cases in the United
States alone (81). In recent studies, it was indicated that
there may be additional genes which contribute to breast
cancer risk. Much more common are multiple
susceptibility genes which have low absolute risk, but
potentially high population-attributable risk. One such
class of genes is the one that codes for enzymes or
receptors which control the metabolism and intracellular
transport of estrogen. It is assumed that, among ethnic
groups, genetic differences exist which affect steroid
hormone metabolism and transport. According to the
polygenic model developed by Henderson and Feilgeson,
there are functionally important polymorphisms in genes
encoding enzymes involved in steroid hormone
biosynthesis and metabolism, which lead to differences in
individual susceptibility to breast cancer and may interact
with exogenous hormone exposures. The genes of
interest are the 17β-hydroxysteroid dehydrogenase 2
(EDH17B2) gene, the cytochrome p450c17a (CYR17)
9
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gene, and the estrogen receptor (ER) gene (Fig. 5). The
primary role of steroid receptors, such as ER, is to
regulate the rate of transcription of certain genes by
binding as a hormone receptor complex to specific
sequences of DNA called hormone response elements
(HREs). Interaction between the receptor and HREs can
result in either up- or down-regulation of transcription
depending upon binding and action of auxiliary factors
specific to the target gene and the tissue. Polymorphisms
in the ER gene may affect estrogen binding and
subsequent transcription in target genes (82).
On the other hand, it was found that AIB1, a member
of the SRC-1 family and a steroid receptor coactivator,
has amplification in approximately 10% and high
expression in 64% of primary breast cancer. AIB1 protein
interacted with estrogen receptors in a ligand-dependent
fashion, and transfection of AIB1 resulted in
enhancement of estrogen-dependent transcription. These
observations identify AIB1 as a nuclear receptor

Ovarian synthesis

coactivator whose altered expression may contribute to
the development of steroid-dependent cancers (83).
Although estrogen was supposed to act mainly as a
growth factor in promoting cancers, new work suggests
that products it forms in the body may also initiate
mutations. Cell culture studies show, for example, that
estrogen metabolites can bind to DNA and trigger
damage. The same compounds also produce cancer in lab
animals. And recent epidemiological studies suggest that
women who have reduced amounts of the enzymes that
help soak up the reactive estrogen byproducts are at
higher risk of developing breast cancer (81).
Metabolic genes and their role in carcinogenesis, as
well as the role of the estrogen byproducts in the
developing cancer are a relatively new area of research
with scant information at present. Studying mutations
and polymorphisms in these and other genes involved in
estrogen metabolism will further our understanding of
breast cancer.

Fig. 5.
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